What is Libtayo (cemiplimab)?
buy Libtayo (cemiplimab): Libtayo (cemiplimab) is a drug that blocks a protein called PD-1. It is used to treat several types of cancer. These include:
Metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. [3].
Advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate.[]
Advanced non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score ≥50%). Patients must either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation, and the tumors must not have EGFR, ALK or ROS1 aberrations.[]
How does Libtayo (cemiplimab) work?
Libtayo (cemiplimab) is a special antibody that targets PD-1. This protein is found on immune cells and some cancer cells. By blocking PD-1, it helps the immune system fight cancer cells[1].
PD-1 ligands PD-L1 and PD-L2 bind to PD-1 on T cells. This stops T-cell growth and cytokine production. Some tumors have more PD-1 ligands, which can hide from the immune system[1].
Where has Libtayo (cemiplimab) been approved?
Libtayo (cemiplimab) has been approved by:
Food and Drug Administration (FDA), US:
September 2018 for advanced CSCC[1]
February 9, 2021 for advanced BCC[6]
February 22, 2021 for advanced NSCLC[7]
European Medical Agency (EMA), European Union
June 28, 2019 for advanced BCC [4]
Health Canada, Canada:
April 10, 2019 for advanced BCC[5]
It is the first treatment for advanced CSCC approved by the FDA. It was approved quickly because it’s a big improvement in treating serious conditions. It also got a special status for CSCC.[3]
Currently, the EMA is checking Libtayo (cemiplimab) for advanced NSCLC and locally advanced BCC. Decisions are expected in mid-2021.[7]
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.
How is Libtayo (cemiplimab) taken?
The recommended dosage is[1]
350 mg, every 3 weeks, intravenous infusion over 30 minutes
Adjustment in dose may be required based on symptoms and experienced side effects[1].
Complete information about Libtayo (cemiplimab) dosage and administration can be found in the official prescribing information listed in our resources section.[1]
Note: Please consult with your treating doctor for personalised dosing.
Are there any known side effects or adverse reactions of Libtayo (cemiplimab)?
Early identification and management are essential to ensure safe use of PD-1 blocking antibodies. Monitor for symptoms and signs of immune-mediated adverse reactions. Evaluate clinical chemistries, including liver and thyroid function, at baseline and periodically during treatment. Withhold or permanently discontinue Libtayo (cemiplimab) and administer corticosteroids based on the severity of reaction. See official prescribing information listed in our resources section[1].
Serious adverse reactions
The serious adverse reactions listed in the prescribing information include[1]:
Immune-mediated pneumonitis
Immune-mediated colitis
Immune-mediated hepatitis
Immune-mediated endocrinopathies
Infusion-related reactions
Common adverse reactions
The common adverse reactions listed in the prescribing information include[1]:
Fatigue
Rash
Diarrhoea
Use in specific populations
Libtayo (cemiplimab) can be fatal for a foetus, it is advised to avoid pregnancies and breastfeeding[1].
Safety and effectiveness in paediatric patients has not been established[1].
Reviews
There are no reviews yet.